Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 2Rectal Neoplasms 1Nasopharyngeal Neoplasms 1Lung Neoplasms 1Esophagitis 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anus Neoplasms 1

Interventions

Gemcitabine 5Cisplatin 5toripalimab 3Radiotherapy, Intensity-Modulated 3Nivolumab 2spartalizumab 1pembrolizumab 1camrelizumab 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Patient Reported Outcome Measures 1Observation 1Magnetic Resonance Spectroscopy 1Interferon beta-1a 1Induction Chemotherapy 1Immunotherapy 1Immunohistochemistry 1Fluorouracil 1Endoscopy 1Carboplatin 1Blood Specimen Collection 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Nasopharyngeal Neoplasms × Induction Chemotherapy × Clear all
NCT05628922 2022-11-29

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Fudan University

Phase 2 Recruiting
198 enrolled
Head & Neck

Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡